<DOC>
	<DOCNO>NCT00855218</DOCNO>
	<brief_summary>This study look whether drug ( sorafenib ) combination chemotherapy deliver directly tumor use bead ( DC Bead ) slow progression disease . The bead use chemotherapy slowly release chemotherapy reduce adverse effect normally occur chemotherapy .</brief_summary>
	<brief_title>A Phase II Randomized , Double-blind , Placebo-controlled Study Sorafenib Placebo Combination With Transarterial Chemoembolization ( TACE ) Performed With DC Bead Doxorubicin Intermediate Stage Hepatocellular Carcinoma ( HCC ) .</brief_title>
	<detailed_description>Safety issue report Adverse Event section . In addition secondary outcome measure , Biomarkers Patient Report Outcome also analyze variable .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Unresectable , multinodular asymptomatic tumor without vascular invasion extrahepatic spread Confirmed Diagnosis HCC : Cirrhotic subject : Clinical diagnosis American Association Study Liver Diseases ( AASLD ) criterion HCC define cirrhotic subject one imaging technique ( Computed tomography [ CT ] scan , Magnetic resonance image [ MRI ] , second generation contrast ultrasound ) show nodule large 2 cm contrast uptake arterial phase washout venous late phase two image technique show radiological behavior nodule 12 cm diameter . Cytohistological confirmation require subject fulfill eligibility criterion . Noncirrhotic subject : For subject without cirrhosis , histological cytological confirmation mandatory Documentation original biopsy diagnosis acceptable Child Pugh class A without ascites Adequate bone marrow , liver renal function assess central lab mean follow laboratory requirement sample within 7 day prior randomization : Patients liver transplantation list advance liver disease define : Child Pugh B C Active gastrointestinal bleeding Encephalopathy Ascites Lesions previously treat local therapy resection HCC , radiofrequency ablation ( RFA ) , percutaneous ethanol injection ( PEI ) cryoablation select target lesion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>TACE</keyword>
	<keyword>DC bead</keyword>
	<keyword>Combination</keyword>
</DOC>